High calcium concentration and calcium oxalate crystals cause significant inaccuracies in the measurement of urinary osteopontin by enzyme linked immunosorbent assay

Urological Research

Volumn 36, Issue 2, 2008, Pages 103-110

  Thurgood, Lauren A ^a   Grover, Phulwinder K ^a   Ryall, Rosemary Lyons ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Biomarker; Calcium oxalate; Enzyme linked immunosorbent assay (ELISA); Osteopontin; Urine; Urolithiasis

Indexed keywords

CALCIUM; CALCIUM OXALATE; OSTEOPONTIN; WEDDELLITE; WHEWELLITE;

ARTICLE; CALCIUM URINE LEVEL; CONCENTRATION (PARAMETERS); ENZYME LINKED IMMUNOSORBENT ASSAY; PRIORITY JOURNAL; URINALYSIS;

BIOLOGICAL MARKERS; CALCIUM; CALCIUM OXALATE; CRYSTALLIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; OSTEOPONTIN; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; UROLITHIASIS;

EID: 44149108858     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-008-0139-3     Document Type: Article

References (39)

1. Denhardt DT, Guo X (1993) Osteopontin: a protein with diverse functions. FASEB J 7:1475-1482
2. Oldberg A, Franzen A, Heinegard D (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Nat Acad Sci USA 83:8819-8823
3. Qin C, Baba O, Butler WT (2004) Post-translational modifications of SIBLING proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 15:126-136
4. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS (2001) Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 280:460-465
5. Hoyer JR, Otvos L Jr, Urge L (1995) Osteopontin in urinary stone formation. Ann NY Acad Sci 760:257-265
6. Shiraga H, Min W, VanDusen WJ, Clayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Neilson EG, Hoyer JR (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89:426-430
7. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F (2001) Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60:1645-1657
8. Asplin JR, Arsenault D, Parks JH, Coe FL, Hoyer JR (1998) Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int 53:194-199
9. Min W, Shiraga H, Chalko C, Goldfarb S, Krishna GG, Hoyer JR (1998) Quantitative studies of human urinary excretion of uropontin. Kidney Int 53:189-193
10. Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinman JG (1998) Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53:952-957
11. Lieske JC, Leonard R, Toback FG (1995) Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol Renal Physiol 268:F604-F612
12. Yamate T, Kohri K, Umekawa T, Amasaki N, Amasaki N, Isikawa Y, Iguchi M, Kurita T (1996) The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells. Eur Urol 30:388-393
13. Yamate T, Kohri K, Konya E, Ishikawa Y, Iguchi M, Kurita T (1999) Interaction between osteopontin on Madin Darby Canine Kidney cell membrane and calcium oxalate crystal. Urol Int 62:81-86
14. Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J (2003) Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14:139-147
15. Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K, Iguchi M, Yamate T, Umekawa T, Suzuki Y, Sinohara H, Kurita T (1993) Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 268:15180-15184
16. Bautista DS, Denstedt J, Chambers AF (1996) Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J Cell Biochem 61:402-409
17. Hoyer JR, Pietrzyk RA, Liu H, Whitson PA (1999) Effects of microgravity on urinary osteopontin. Am Soc Nephrol 10:S389-393
18. Nishio S, Hatanaka M, Takeda H, Iseda T, Iwata H, Yokoyama M (1999) Analysis of urinary concentrations of calcium phosphate crystal-associated proteins: alpha2-HS-glycoprotein, prothrombin F1, and osteopontin. J Am Soc Nephrol 10:S394-S396
19. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T (2000) Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 77:487-498
20. Yasui T, Fujita K, Hayashi Y, Ueda K, Kon S, Maeda M, Uede T, Kohri K (1999) Quantification of osteopontin in the urine of healthy and stone-forming men. Urol Res 27:225-230
21. Dean CJ, Macardle PJ, Ryall RL (2000) The effect of the presence of calcium oxalate crystals on the measurement of prothrombin fragment 1 in urine. In: Rodgers AL, Hibbert BE, Hess B, Khan SR, Preminger GM (eds) Urolithiasis 200. University of Cape Town, Cape Town, pp 150-152
22. Ryall RL, Chauvet MC, Grover PK (2005) Intracrystalline proteins and urolithiasis: a comparison of the protein content and ultrastructure of urinary calcium oxalate monohydrate and dihydrate crystals. BJU Int 96:654-663
23. Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH, Zepeda S, De Yoreo JJ (2004) Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Nat Acad Sci USA 101:1811-1815
24. Brown P, Ackermann D, Finlayson B (1989) Calcium oxalate dihydrate (weddellite) precipitation. J Cryst Growth 98:285-292
25. Ryall RL, Hibberd CM, Marshall VR (1985) A method for studying inhibitory activity in whole urine. Urol Res 13:285-289
26. Lieske JC, Hammers MS, Hoyer JR, Toback FG (1997) Renal cell osteopontin production is stimulated by calcium oxalate monohydrate crystals. Kidney Int 51:679-686
27. Huang H-S, Ming-Chieh MA, Chen C-F, Chen J (2003) Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 62:1123-1128
28. Nishio S, Hatanaka M, Takeda H, Aoki K, Iseda H, Yokoyama M (2001) Calcium phosphate crystal-associated proteins: alpha-2-HS-glycoprotein, prothrombin fragment 1 and osteopontin. Int J Urol 8:S58-S62
29. Ryall RL, Grover PK, Thurgood LA, Chauvet MC, Fleming DE, van Bronswijk W (2007) The importance of a clean face: the effect of different washing procedures on the association of Tamm-Horsfall glycoprotein and other urinary proteins with calcium oxalate crystals. Urol Res 35:1-14
30. Meyer JL, Smith LH (1975) Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Invest Urol 13:36-39
31. Kazanecki CC, Kowalski AJ, Ding T, Rittling SR, Denhardt DT (2007) Characterization of anti-osteopontin monoclonal antibodies: binding sensitivity to post-translational modifications. J Cell Biochem 102:925-935
32. Kleinman JG, Wesson JA, Hughes J (2004) Osteopontin and calcium stone formation. Nephron Physiol 98:43-47
33. Krakauer T (1998) Variability in the sensitivity of nine enzyme-linked immunosorbant assays (ELISAs) in the measurement of human interleukin 6. J Immunol Methods 219:161-167
34. Vordermark D, Said HM, Katzer A, Kuhnt T, Hänsgen G, Dunst J, Flentje M, Bache M (2006) Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 6:207
35. Hoyer JR, Asplin JR, Otvos L (2001) Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60:77-82
36. Addadi L, Weiner S (1985) Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proc Natl Acad Sci USA 82:4110-4114
37. Yamaguchi H, Igarashi M, Hirata A, Tsuchiya H, Sugiyama K, Morita Y, Jimbu Y, Ohnuma H, Daimon M, Tomonaga M, Kato T (2004) Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 51:499-504
38. Gang X, Ueki K, Kon S, Maeda M, Naruse T, Nojima Y (2001) Reduced urinary excretion of intact osteopontin in patients with IgA nephropathy. Am J Kidney Dis 37:374-379
39. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW (2006) Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12:432-441